ReNeuron Group plc (LON:RENE – Get Free Report) passed below its 200-day moving average during trading on Friday . The stock has a 200-day moving average of GBX 4.12 ($0.05) and traded as low as GBX 3.28 ($0.04). ReNeuron Group shares last traded at GBX 3.38 ($0.04), with a volume of 177,373 shares.
ReNeuron Group Price Performance
The business has a 50 day moving average price of GBX 3.38 and a two-hundred day moving average price of GBX 4.12. The stock has a market cap of £1.93 million, a PE ratio of -37.50 and a beta of 0.69. The company has a debt-to-equity ratio of 14.25, a quick ratio of 2.02 and a current ratio of 1.51.
ReNeuron Group Company Profile
ReNeuron Group plc researches, develops, and commercializes cell-based therapies in the United Kingdom. The company engages in the development of CTX stem cell therapy candidate for treating stroke disability; and human retinal progenitor cell therapy that is in Phase 2 clinical trial for treating retinitis pigmentosa, a blindness-causing disease.
Featured Stories
- Five stocks we like better than ReNeuron Group
- Best Aerospace Stocks Investing
- 3 Stocks Leading the U.S. Agriculture Comeback
- Bank Stocks – Best Bank Stocks to Invest In
- How to Use Put Debit Spreads to Profit From Falling Stocks
- What Are the FAANG Stocks and Are They Good Investments?
- Alphabet Changes the Narrative with Its First-Ever Dividend
Receive News & Ratings for ReNeuron Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ReNeuron Group and related companies with MarketBeat.com's FREE daily email newsletter.
